@BrianJScanlan@FlemmingBruce@BIO99_BIO99 Wrong! In late 2020 when it was announced that the UK MHRA would join the Access Consortium on Jan 1, 2021 it was not only noticed but actively discussed! Checking dates is a crucial part of DD $NWBO
@litmpodcast Prior to NICE the local level decided if an approved drug/treatment could be prescribed (and paid for) by NHS. NICE was created to evaluate the cost/benefit of approved drugs/treatments. If recommended by NICE it must be available throughout the NHS. Key word is approved! #NWBO
@justinkeister5 @SECEnfDirector $NWBO Has anything been done to stop this illegal practice - after all it’s been 10 years since the Rolling Stone article was published. Who keeps protecting the big investment banks?
“It’s already underhanded to engage in #marketmanipulation, but to do so at the expense of cancer patients, some of whom have no other treatments to place their hopes on, is unconscionable,” said Laura Posner at Cohen Milstein.
#spoofing
https://t.co/BRe8bQlK8W via @WSJ
“It’s already underhanded to engage in #marketmanipulation, but to do so at the expense of cancer patients, some of whom have no other treatments to place their hopes on, is unconscionable,” said Laura Posner at Cohen Milstein.
#spoofing
https://t.co/BRe8bQlK8W via @WSJ
Is there something special, something capable of inducing broad CPI-like anti-tumor immunity, of engaging both macrophage mediated phagocytosis and NK cell mediated ADCC simultaneously?
Again I find facts #2 and #3 hard to square, and important to understand.
AMAZING: A blind man has regained his sight after receiving the first implant worldwide of an artificial cornea developed by Israeli startup CorNeat Vision. Wonderful news which will impact millions of lives
@GantosJ@beat_cov 4 German biotechs just launched an initiative to drive Covid therapeutics targeting all stages of the disease and repurposing drugs already in the pipeline. This is a global challenge that requires more collaborations like $PFE $BNTX and funding
#BEATCOV ist ein Zusammenschluss von vier deutschen, mittelständischen Biotechunternehmen mit fortgeschrittenen #COVID19-Therapieansätzen, die klare Entscheidungen zur Förderung therapeutischer Maßnahmen fordern. @AiCuris @AtrivaTx@ImmunicInc#InflaRx
https://t.co/Yo2WgwlhhQ
@LTCMotes@CarzSteve $NWBO The Galbraith Lecture is given annually by a guest neurosurgeon who has made significant contributions to the field of neurosurgery..
https://t.co/RMkofQFtAb